Gefitinib - A novel targeted approach to treating cancer

Roy S. Herbst, Masahiro Fukuoka, José Baselga

Research output: Contribution to journalReview articleResearchpeer-review

298 Citations (Scopus)


Twenty years after the epidermal growth factor receptor (EGFR) was identified as a potential anticancer target, the EGFR inhibitor gefitinib (Iressa; AstraZeneca) has been approved for the treatment of patients with advanced non-small-cell lung cancer in many countries. Studies have indicated its potential for treating patients with other types of solid tumours. Investigation of gefitinib has not only increased our knowledge about the biology of EGFR signalling, but is contributing to our evolving understanding of which tumours are EGFR dependent.
Original languageEnglish
Pages (from-to)956-965
JournalNature Reviews Cancer
Issue number12
Publication statusPublished - 1 Dec 2004


Dive into the research topics of 'Gefitinib - A novel targeted approach to treating cancer'. Together they form a unique fingerprint.

Cite this